AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04537208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM-AS03 (high-dose)
Description: Pharmaceutical form: liquid; route of administration: intramuscular injection
Study NCT04537208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM (high-dose) without adjuvant
Description: Pharmaceutical form: liquid; route of administration: intramuscular injection
Study NCT04537208 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% normal saline)
Description: Pharmaceutical form: liquid; route of administration: intramuscular injection
Study NCT02256384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Acoustic Monitor
Description: Examine the reliability and accuracy of the respiratory acoustic monitor.
Study NCT04564807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-Based Insomnia Education Program
Description: Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data.
Study NCT04564807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHUTi Intervention
Description: Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention.
Study NCT00210353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorambucil (drug)
Description: chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment, two weeks rest, chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
Study NCT00210353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab+chlorambucil
Description: rituximab 375 mg/m2 iv, d1, 8, 15, 22, chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment, ; two weeks rest; chlorambucil 6 mg/m2 os, daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
Study NCT00210353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
Study NCT02030925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3718
Study NCT02030925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Study NCT01541943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Once daily, administered orally, 8 week
Study NCT01541943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Once daily, administered orally, 8 week
Study NCT01541943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, administered orally, 8 week
Study NCT01541943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-040XC
Description: Once daily, administered orally, 8 week
Study NCT04046016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Liporaxel and microdose 18F-Liporaxel administration study was conducted in two breast cancer patients. Therapeutic dose of Liporaxel was 200 mg/m2 and 18F-Liporaxel was 0.98-2.9 μg (185-555 MBq).
Study NCT01263431 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: Each of the main haemorrhoid is dissected and the apex is ligated and then cut, near to the dentate line
Study NCT01263431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemorrhoidal dearterialization
Description: A special instrument (THD, G.F., Medical Division, Correggio, Italy )with an incorporated Doppler probe is used to detected the six terminal branches of the superior rectal artery which are ligated above the dentate line, then a running suture is performed in order to obtain a mucopexy
Study NCT00113399 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim
Study NCT00113399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Study NCT04019574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Placebo as a bolus injection
Study NCT02533739 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive and neuropsychological assesment
Study NCT00113399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Study NCT00113399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fluorouracil
Study NCT00113399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel
Study NCT00113399 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Study NCT02533739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and neuropsychological assesment
Study NCT01106651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: One 100 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
Study NCT01106651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: One 300 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
Study NCT01896999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03326765 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: * Epworth sleepiness scale~* Pittsburgh sleep quality Index (PSQI)~* EQ-5D Adults~* Pediatric Daytime Sleepiness scale (PDSS)~* Sleep disturbance Scale for Children (SDSC~* EQ-5D Children~* Sleaping diary
Study NCT03326765 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: electroencephalogram (EEG)
Description: is an electrophysiological monitoring method to record electrical activity of the brain
Study NCT03326765 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: polysomnography
Description: type of sleep study, is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine
Study NCT01106651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihyperglycemic agent(s)
Description: Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\] inhibitors, metformin, insulin \[all types\]) and their combinations (sulfonylurea agent and insulin \[all types\], metformin and insulin \[all types\], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\]) are used as per protocol specifications.
Study NCT01896999 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT01896999 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT01106651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antihyperglycemic agent(s)
Description: Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\] inhibitors, metformin, insulin \[all types\]) and their combinations (sulfonylurea agent and insulin \[all types\], metformin and insulin \[all types\], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\]) are used as per protocol specifications.
Study NCT01106651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
Study NCT01779856 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: REVEAL Insertable Cardiac Monitor (ICM)
Study NCT04345861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine + placebo
Description: hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11)
Study NCT03335215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive remediation
Description: The innovative nature of this program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains that may have an impact on the maintenance of the therapeutic contract will be offered to patients. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context. The different procedures of neuropsychological management (facilitation, use of preserved capacities and compensation) will help to integrate the concepts and addictological strategies necessary to maintain the therapeutic contract taking into account cognitive impairments.
Study NCT01896999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT03318406 — intervention group
Intervention type: DEVICE
Intervention: Bronchoscopic Thermal Vapor Ablation
Description: Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
Study NCT03532100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Torsionally adaptive prosthesis with 0:1 coupling ratio
Description: The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 0:1 means there will be no coupling between the transverse- and sagittal-plane motion. That is, regardless of any motion in the sagittal plane, there will be zero motion in the transverse plane.
Study NCT01377987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 4 mg/kg, once daily before bed, for 7 days
Study NCT04345861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine + azithromycin
Description: Combination hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11) Azithromycin 500mg (day 1) then 250 mg (Day 2 to Day 5)
Study NCT03603587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Biopsy 4 to 5 mm from the distal part of the tips of the excision pieces. Three biopsies of 3 mm, made with punch, occipital hair zone (ZT) A completely painless sample, using a swab (soaked with a buffer solution) on the scalp of the ZH and ZT zone.
Study NCT03603587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Blood sample will be collected for performed for HIV serology, B and C hepatitis.
Study NCT03603587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: questionnaire on sun exposure
Description: Questionnaire on sun exposure will be completed by patients.
Study NCT03603587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: examination of the scalp
Description: A complete examination of the scalp will be completed by dermatologist.
Study NCT03603587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Norwood scale
Description: Norwood scale measure the evolution of baldness. It will be completed by dermatologist.
Study NCT03603587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: questionnaire of clinicals signs
Description: Questionnaire of clinicals signs will be completed by dermatologist and patient.
Study NCT03603587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: scinexa score
Description: It's a assessment score of skin aging. It will be completed by dermatologist.
Study NCT03603587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: questionnaire of the history of the hair loss
Description: Questionnaire of the history of the hair loss will be completed by dermatologist and patient.
Study NCT01377987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 mg/kg, once daily before bed, for 7 days
Study NCT04500080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PE Intervention
Description: Each single exercise session will last for one hour and will consist of a combination of the following elements:~* Aerobic Exercise (AE): 20-30 minutes at moderate-high intensity, from 60 to 80% of the maximum heart rate (% HRmax).~* Resistance Exercise (RE): 30 minutes of strength activity of the major muscle groups.~* Neuromotor Exercise (NE): will be integrated with strength exercises and will consist of jumping, balance and coordination activities
Study NCT02453945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Support Bra
Description: A ClearPoint Medical support bra
Study NCT04181593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: Omega 3 fatty acid Softgels
Study NCT04181593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Mineral oil Softgels
Study NCT03197987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocuff
Description: Endocuff-assisted colonoscopy
Study NCT03769714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution for Injection
Description: Injection of 20mL of 0.9%Normal Saline
Study NCT03769714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable suspension) for administration into the surgical site to produce postsurgical analgesia.
Study NCT01238380 — intervention group
Intervention type: OTHER
Intervention: patient care pathway
Description: Stage 1: Urinary c-peptide creatinine ratio (UCPCR); if positive progress to Stage 2.~Stage 2: Pancreatic auto-antibodies measurement (GAD65 \& IA2); if negative progress to genetic testing.~Genetic testing for HNF1A, HNF4A, GCK. If positive, progress to Stage 3.~Stage 3: review and potential change of diabetes treatment. Monitor success via use of three standardised health and quality of life questionnaires and Hba1c pre-treatment change and at 1, 3, 6 and 12 months post-treatment change.
Study NCT01401556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: case management
Study NCT01401556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multifaceted quality improvement intervention
Study NCT03532100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Torsionally adaptive prosthesis with 1:6 coupling ratio
Description: The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:6 means there will be one degree of motion in the transverse plane for every six degrees of motion in the sagittal plane.
Study NCT03197987 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cap
Description: Cap-assisted colonoscopy
Study NCT02130830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical 2,5% lidocaine + 2,5% prilocaine gel
Description: The topical gel is administered in the anal canal at the moment of the anoscopy
Study NCT02130830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
Study NCT04420884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazostinag
Description: Dazostinag intravenous infusion.
Study NCT04420884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous infusion.
Study NCT04420884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: Carboplatin or Cisplatin intravenous infusion
Study NCT04420884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil intravenous infusion
Study NCT03326765 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Actigraphy
Description: type of sleep study based on bracelet around the wrist
Study NCT04059484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant
Description: Pharmaceutical form: Capsule~Route of administration: Oral
Study NCT04059484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Pharmaceutical form: Solution for injection~Route of administration: Intramuscular
Study NCT04059484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Pharmaceutical form:Tablets or capsules~Route of administration: Oral
Study NCT04059484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Pharmaceutical form: Tablets or capsules~Route of administration: Oral
Study NCT04059484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Pharmaceutical form: Tablets or capsules~Route of administration: Oral
Study NCT04059484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Pharmaceutical form: Tablets or capsules~Route of administration: Oral
Study NCT02241655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a pragmatic EEG-guided anesthetic protocol
Study NCT02668770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGN1703
Description: Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group.
Study NCT02668770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dose Escalation and Dose Expansion Group Dose: 3 mg/kg by vein on Day 8 of a 21 day cycle.
Study NCT02120300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally
Study NCT02120300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: 400 mg tablet administered orally once daily
Study NCT02120300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT00657293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm training program
Description: Patients will undergo a specific arm training program (ATP) three times a week for the duration of the 6 week program. The ATP will consist predominantly of resistance exercises. Muscle groups targeted during the ATP will include deltoid, biceps and triceps, pectoralis and latissimus. Subjects will train using multi station gym equipment and free weights.
Study NCT00657293 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Purdue pegboard test (sham)
Description: In an attempt to make the groups comparable in terms of attention, the control group will perform the purdue pegboard test of finger dexterity. The tasks will be performed in a sitting position with the arms supported on a table. This test will consist of 4 timed tasks where as many pins as possible will be placed on a pegboard in a given time. Performance of the pegboard test is likely to improve with practice which may serve to motivate the patients to continue practicing over the 6-week period. Subjects will perform this activity 3 times per week with supervision provided by a physiotherapist.
Study NCT03639623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar
Description: Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food
Study NCT01830283 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: varicella vaccine
Description: The providers would get varicella vaccine
Study NCT01830283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: varicella vaccine
Description: The providers would get varicella vaccine
Study NCT03754127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial direct current stimulation
Study NCT03754127 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Sham transcranial direct current stimulation